Samyang Holdings Establishes and Spins Off 'Samyang Biopharm' to Strengthen Pharmaceutical and Bio Business Competitiveness

Spin-Off of Samyang Holdings and Samyang Biopharm as Separate Entities
KOSPI Relisting on November 24... Enhancing Competitiveness Through Independent and Accountable Management

Samyang Holdings, the holding company of Samyang Group, announced on May 30 that it has spun off its BioPharm division as a separate business entity, establishing 'Samyang Biopharm.' This comes four years after the company absorbed its pharmaceutical and bio subsidiary, Samyang Biopharm, in 2021, and is now separating it once again.

The exterior view of Samyang Discovery Center located in Pangyo, Seongnam, Gyeonggi Province. Samyang Holdings

This spin-off will be carried out as a physical division, in which Samyang Holdings shareholders will receive shares in both the existing and the newly established company in proportion to their current ownership. The split ratio between the surviving company, Samyang Holdings, and the new company, Samyang Biopharm, is 0.9039233 and 0.0960767, respectively. This ratio was determined based on the current book value of net assets.

If all procedures proceed as planned, Samyang Biopharm will officially launch as an independent corporation on November 1, 2025, and is scheduled to be listed on the Korea Exchange (KOSPI) on November 24, 2025. Trading of Samyang Holdings shares will be temporarily suspended from October 30, 2025, the day before the record date for new share allocation, until the day before the change of listing and relisting date.

Samyang Holdings is currently led by co-CEOs Um Taeung and Kim Kyungjin. After the spin-off, Um Taeung will serve as CEO of the holding company, Samyang Holdings, focusing on its management, while Kim Kyungjin will lead Samyang Biopharm, which will be responsible for the group’s pharmaceutical and bio businesses.

Samyang Holdings has decided to separate the business in order to have the BioPharm division re-evaluated for its value, and to respond proactively to the rapidly changing pharmaceutical and bio industry environment through independent management by professional executives.

Um Taeung, CEO of Samyang Holdings, stated, "With the establishment and spin-off of Samyang Biopharm, Samyang Holdings will focus on its role as a pure holding company, concentrating on the management of its subsidiaries, while Samyang Biopharm will be able to enhance management efficiency through independent and accountable management."

Since 1993, Samyang Group has succeeded in developing the first biodegradable surgical suture in Korea, and currently holds the number one global market share for suture yarns based on supply volume. In addition, the company has strengthened its pharmaceutical business with a focus on anticancer drugs, building a portfolio of seven solid tumor and five hematologic cancer treatments. Recently, it completed a new injectable anticancer drug manufacturing facility with an annual production capacity of five million vials, and obtained GMP (Good Manufacturing Practice) certification in Japan and Europe. Furthermore, through research and development of its proprietary gene delivery platform 'SENS (Selectivity Enabling Nano Shells),' the company is accelerating the development of next-generation new drugs.

This content was produced with the assistance of AI translation services.